What are you looking for?
Need help finding what you are looking for? Contact Us

PUBLISHER: FirstWord Group | PRODUCT CODE: 1473275

Cover Image

PUBLISHER: FirstWord Group | PRODUCT CODE: 1473275

Wet Age-Related Macular Degeneration - KOL Insight

DELIVERY TIME: 1-2 business days
Multi User License (PDF)
USD 39950

Add to Cart

With the introduction of Roche's Vabysmo challenging Bayer/Regeneron's Eylea, the dynamics of first-line choices are shifting. Meanwhile, off-label Avastin remains a cost-effective option, though its usage may wane with new advancements. As we look to the future, the focus sharpens on longer treatment intervals, improved visual acuity, and less invasive options, highlighting the potential of gene therapies, tyrosine kinase inhibitors, and innovative drugs like D 4517.2 and Axpaxli. This pivotal moment in wAMD treatment calls for a strategic pivot towards addressing unmet needs and embracing novel therapeutic pathways.

Table of Contents

Executive summary (14)

Treatment algorithm

Research objectives (2)

VEGF inhibitors (71)

  • Marketed therapies (71)
    • Vabysmo (faricimab; Roche) (21)
    • Eylea (aflibercept; Bayer/Regeneron Pharmaceuticals) (21)
    • Lucentis (ranibizumab; Roche/Novartis) (18)
    • Beovu (brolucizumab; Novartis) (11)

VEGF inhibitors (70)

  • Marketed therapies used off label (13)
    • Avastin (bevacizumab; Roche) (13)
  • Pipeline therapies (57)
    • Sozinibercept (OPT-302; Opthea) (16)
    • D-4517.2 (Asvattha Therapeutics) (17)
    • Lytenava (bevacizumab ophthalmic; Outlook Therapeutics) (14)
    • Yesafili (aflibercept biosimilar; Momenta Pharmaceuticals/Viatris/Biocon) (10)

Tyrosine kinase inhibitors (24)

  • Pipeline therapies (24)
    • Axpaxli (axitinib intravitreal implant/OTX-TKI; Ocular Therapeutix) (12)
    • Vorolanib (Equinox Sciences/EyePoint Pharmaceuticals) (12)

Gene therapy (32)

  • Pipeline therapies (32)
    • ABBV-RGX-314 (REGENXBIO/AbbVie) (22)
    • Ixoberogene soroparvovec (Ixo-vec; Adverum Biotechnologies) (10)

Future treatment paradigm (15)

  • Key insights summary (15)
    • Pharma companies developing wAMD therapies should focus on treatment duration, ease of administration, safety and new therapeutic pathways (3)

Appendix (3)

  • KOL details (3)
    • KOLs from the USA (1)
    • KOLs from Europe (1)
Have a question?

Jeroen Van Heghe

Manager - EMEA



Christine Sirois

Manager - Americas


Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!